CLINICAL_TRIALS trial_result · 2022-12-23

Clinical Trial Update: A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa [Phase 2]

Phase 2 trial investigating a neurokinin-1 receptor antagonist for pruritus in Epidermolysis Bullosa has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Stanford University | Conditions: Epidermolysis Bullosa | Phase 2 | Status: COMPLETED | Results posted: 2022-12-23